ArticleJournal of managed care & specialty pharmacy2023
Estimated discounts generated by Medicare drug negotiation in 2026.
Article in Journal of managed care & specialty pharmacy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Are Glucagon-Like Peptide 1 Receptor Agonists and Bariatric Surgery the Answer to Childhood Obesity?Current atherosclerosis reports · 2025Review
- Selected drugs, therapeutic alternatives, and price benchmarks for IPAY 2027 Medicare drug price negotiation.Journal of managed care & specialty pharmacy · 2025Article
- Advancing the conversation: 30 years of scholarship in managed care pharmacy.Journal of managed care & specialty pharmacy · 2025Article
- The high costs of anticancer therapies in the USA: challenges, opportunities and progress.Nature reviews. Clinical oncology · 2024Review
- Concentration of spending and share of specialty drug spending in Medicare Part D over a 10-year period.Journal of managed care & specialty pharmacy · 2024Article
- Market Transparency in Medicine Pricing: Pathways to Fair Pricing.PharmacoEconomics · 2024Article
- Medicare drug price negotiation: The complexities of selecting therapeutic alternatives for estimating comparative effectiveness.Journal of managed care & specialty pharmacy · 2024Article
- Trends in Proportion of Medicare Part D Claims Subject to 340B Discounts, 2013-2020.JAMA health forum · 2023Article
- Nonfederal average manufacturer price to estimate savings generated by minimum discounts under the Inflation Reduction Act.Journal of managed care & specialty pharmacy · 2023Article
- The Association of 340B Program Drug Margins with Covered Entity Characteristics.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.